Clinical Research Directory

Inclusion Criteria: * Subjects who voluntarily join the study, sign the informed consent form, and have good compliance. * Aged from 18 to 75 years; Eastern Cooperative Oncology Group performance status score: 0-2; at least 12 weeks expected survival period. * Multiple myeloma with diagnostic records and meeting the International Myeloma Working Group (IMWG) diagnostic criteria * There are measurable lesions present * The function of main organs is normal. * Subjects need to adopt effective methods of contraception. Exclusion Criteria: * Subjects who have taken Chinese patent medicines with anti-tumor indications in the drug instructions that National Medical Products Administration approved within 2 weeks before the first administration. * Subjects who received targeted therapy or immunotherapy within 3 weeks before the first medication * Subjects who is known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent. * Subjects who has had or currently has other malignant tumors within the past 3 years prior to the first use of medication * Subjects who with unrelieved toxic reactions above Common Terminology Criteria for Adverse Events (CTC AE) grade 1 caused by any previous treatment * Subjects who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication * Subjects who have experienced arterial/venous thrombotic event occurred within 6 months prior to the first administration * Subjects with a history of psychotropic drug abuse unable to quit or with mental disorders; * Subjects with any severe and/or uncontrolled disease * According to the judgment of the investigators, there are accompanying diseases that seriously endanger the safety of patients or affect the completion of the study.